Q-omics provides the consensus-scored MIR548AR profile across patient tissues and cancer cell-line models. MIR548AR expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR548AR is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, MIR548AR RNA expression shows 13,448 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, BLCA, and DLBC as cancer lineages where MIR548AR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548AR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548AR survival associations across molecular data types. MIR548AR RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548AR RNA expression–survival associations across cancer types. High MIR548AR expression shows unfavorable associations in KIRC, SKCM, UVM and CESC, but favorable associations in BLCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR548AR RNA expression.
This table summarizes MIR548AR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548AR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548AR shows lower tumor expression in BRCA and KICH and higher tumor expression in BLCA, KIRC, CHOL and PAAD. The BLCA box plot shows higher MIR548AR RNA expression in tumor versus normal tissue (log2 FC = +0.899, t-test p = .003).
This table shows molecular features associated with MIR548AR in patient tissues and cancer cell lines. In patient samples, MIR548AR shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
